StockNews.com Lowers Alimera Sciences (NASDAQ:ALIM) to Hold

Alimera Sciences (NASDAQ:ALIM) was downgraded by equities research analysts at StockNews.com from a “buy” rating to a “hold” rating in a research note issued on Tuesday.

Separately, Maxim Group assumed coverage on shares of Alimera Sciences in a research report on Monday, March 25th. They set a “buy” rating and a $10.00 price objective on the stock.

Alimera Sciences Stock Performance

Shares of ALIM opened at $3.46 on Tuesday. The business has a 50-day simple moving average of $3.73 and a two-hundred day simple moving average of $3.65. The company has a quick ratio of 2.31, a current ratio of 2.39 and a debt-to-equity ratio of 1.40. Alimera Sciences has a 52 week low of $1.56 and a 52 week high of $4.38. The stock has a market cap of $181.13 million, a price-to-earnings ratio of -1.60 and a beta of 1.18.

Alimera Sciences (NASDAQ:ALIM) last announced its quarterly earnings data on Thursday, March 7th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.09). Alimera Sciences had a negative net margin of 24.93% and a negative return on equity of 130.90%. The company had revenue of $26.31 million for the quarter, compared to the consensus estimate of $25.10 million. During the same quarter last year, the firm posted ($0.54) earnings per share. On average, analysts expect that Alimera Sciences will post 0.03 EPS for the current year.

Institutional Investors Weigh In On Alimera Sciences

Several institutional investors and hedge funds have recently modified their holdings of the stock. Stonepine Capital Management LLC boosted its position in shares of Alimera Sciences by 0.4% during the fourth quarter. Stonepine Capital Management LLC now owns 3,999,459 shares of the biopharmaceutical company’s stock worth $17,278,000 after acquiring an additional 15,773 shares during the last quarter. Worth Venture Partners LLC bought a new stake in Alimera Sciences in the 3rd quarter valued at $1,840,000. Finally, AIGH Capital Management LLC purchased a new stake in Alimera Sciences in the 3rd quarter worth $7,355,000. Institutional investors own 99.83% of the company’s stock.

Alimera Sciences Company Profile

Alimera Sciences, Inc, a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).